TY - JOUR
T1 - Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel
AU - Torrisi, Rosalba
AU - Balduzzi, Alessandra
AU - Ghisini, Raffaella
AU - Rocca, Andrea
AU - Bottiglieri, Luca
AU - Giovanardi, Filippo
AU - Veronesi, Paolo
AU - Luini, Alberto
AU - Orlando, Laura
AU - Viale, Giuseppe
AU - Goldhirsch, Aron
AU - Colleoni, Marco
PY - 2008/9
Y1 - 2008/9
N2 - Background: No specific treatment guidelines are available for triple-negative breast cancers, defined by a lack of expression of estrogen (ER), progesterone (PgR), and HER2 receptors. Patients and methods: We investigated in patients with T2-T3 N0-3 ER, PgR 2 non-hematological toxicity was observed in three and two patients during ECF and paclitaxel, respectively. The 2-year disease free survival (DFS) was 87.5% (95% CI 74.7-100%). No significant correlation was observed between EGFR staining and either pCR or DFS. Conclusions: Preoperative cisplatin containing chemotherapy followed by paclitaxel induced an high pCR rate in a population of triple-negative breast cancer. The impact of this schedule on long-term outcome should be investigated in larger series.
AB - Background: No specific treatment guidelines are available for triple-negative breast cancers, defined by a lack of expression of estrogen (ER), progesterone (PgR), and HER2 receptors. Patients and methods: We investigated in patients with T2-T3 N0-3 ER, PgR 2 non-hematological toxicity was observed in three and two patients during ECF and paclitaxel, respectively. The 2-year disease free survival (DFS) was 87.5% (95% CI 74.7-100%). No significant correlation was observed between EGFR staining and either pCR or DFS. Conclusions: Preoperative cisplatin containing chemotherapy followed by paclitaxel induced an high pCR rate in a population of triple-negative breast cancer. The impact of this schedule on long-term outcome should be investigated in larger series.
KW - Breast cancer
KW - Platinum based chemotherapy
KW - Preoperative chemotherapy
KW - Triple negative tumors
UR - http://www.scopus.com/inward/record.url?scp=47549084272&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=47549084272&partnerID=8YFLogxK
U2 - 10.1007/s00280-007-0652-z
DO - 10.1007/s00280-007-0652-z
M3 - Article
C2 - 18064460
AN - SCOPUS:47549084272
SN - 0344-5704
VL - 62
SP - 667
EP - 672
JO - Cancer Chemotherapy and Pharmacology
JF - Cancer Chemotherapy and Pharmacology
IS - 4
ER -